PR95172

CAMBRIDGE, England, March 25, 2022 /PRNewswire=KYODO JBN/ --

Abcam (https://corporate.abcam.com/) (AIM:ABC); (NASDAQ:ABCM), today announced

that it has received six recognitions from CiteAb at their annual industry

awards (https://www.citeab.com/awards/2022), the highest of any participant

evaluated this year. This record number of acknowledgments follows a year of

substantial investment for Abcam to enable life sciences researchers from

academia and industry to advance discoveries and deliver faster breakthroughs.

First and foremost, Abcam was recognized for its initiatives to improve

standards in the reagent industry. Its "Recombinant Multiclonal" range, which

combines the benefits of recombinant monoclonal and polyclonal antibodies, was

awarded "Innovation of the Year" by a panel of experts while Abcam was highly

commended in the "Recombinant Antibody Supplier of the Year" category. The

Company also won the "Supplier Succeeding in KO Validation" award for its

antibody validation program

(https://www.abcam.com/primary-antibodies/knockout-validation). All three

awards demonstrate Abcam's commitment to continually improving scientific

reproducibility in life sciences, which benefits the research community and

society globally.

Prof. Giovanna Roncador, Head of the Monoclonal Antibodies Unit/Biotechnology

Program at the Spanish National Cancer Research Center (CNIO), Founder and

Chair of EuroMabNet and recipient of the 2022 CiteAb award for "Significant

Individual Impact

(https://www.citeab.com/awards/2022/award-for-significant-individual-impact)"

said: "As a cancer researcher and antibody engineer, I firmly believe that

advancing science goes hand in hand with improving standards for reagent

quality. I am delighted but not surprised to see Abcam's success in the CiteAb

Awards, as, this year again, they have taken a number of strides forward to

deliver the scientific community the tools they need for success."

Dr. Alejandra Solache, SVP Research and Development at Abcam and recipient of

the 2021 CiteAb award for "Significant Individual Impact

(https://corporate.abcam.com/13452-2/)" commented: "We are excited to see our

dedication to delivering higher standards being acknowledged as we continually

look for new ways in which we can break barriers and set new industry standards

for improving reproducibility in science. Thank you to CiteAb, the judging

panels and the researchers with whom we share the same passion to drive life

sciences forward."

Finally, this year's CiteAb awards also recognize Abcam's effort to address the

growing demand of the sector for high-performance, reproducible, off-the-shelf

assays with the acquisition of BioVision for $340M

(https://corporate.abcam.com/bvii/). Offering a platform for greater innovation

and increasing access to biochemical assays and cellular assays, the deal is

recognized for its potential to lay the foundations for future positive impact

across the life sciences sector.

Abcam's 2022 full list of recognitions include:

Acquisition of the Year

(https://www.citeab.com/awards/2022/acquisition-of-the-year) – Winner

(BioVision)

Innovation of the Year (https://www.citeab.com/awards/2022/innovation-award) –

Winner (Recombinant Multiclonal range)

Supplier Succeeding in KO validation

(https://www.citeab.com/awards/2022/supplier-succeeding-in-ko-validation) –

Winner

Recombinant Antibody Supplier of the Year

(https://www.citeab.com/awards/2022/recombinant-antibody-supplier-of-the-year)

- Highly Commended

Supplier Succeeding in Cancer Research

(https://www.citeab.com/awards/2022/supplier-succeeding-in-cancer-research) -

Highly Commended

Supplier Succeeding in Sars-Cov-2 research

(https://www.citeab.com/awards/2022/supplier-succeeding-in-sars-cov-2-research)

- Highly Commended

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes

high-quality biological reagents and tools that are crucial to research, drug

discovery and diagnostics. Working across the industry, the Company supports

life scientists to achieve their mission, faster.

Abcam partners with life sciences organizations to co-create novel binders for

use in drug discovery, in vitro diagnostics and therapeutics, driven by the

Company's proprietary discovery platforms and world-leading antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the

global understanding of biology and causes of disease, which enables new

treatments and improved health. The Company's pioneering data-sharing approach

gives scientists increased confidence in their results by providing validation,

user comments and peer-reviewed citations for its 90,000 products.

With a direct presence in America, Asia and Europe, many of Abcam's over

1,700-strong team are located in the world's leading life sciences research

hubs, complementing a global network of service and support.

To find out more, please visit www.abcam.com (http://www.abcam.com/) and

corporate.abcam.com (https://corporate.abcam.com/)

Logo - https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg

SOURCE: Abcam